UK Markets close in 4 hrs 19 mins
  • FTSE 100

    6,391.64
    -40.53 (-0.63%)
     
  • FTSE 250

    19,592.12
    -197.44 (-1.00%)
     
  • AIM

    1,032.74
    +0.98 (+0.09%)
     
  • GBP/EUR

    1.1215
    -0.0015 (-0.14%)
     
  • GBP/USD

    1.3333
    -0.0026 (-0.1920%)
     
  • BTC-GBP

    14,418.24
    +0.20 (+0.00%)
     
  • CMC Crypto 200

    381.82
    +12.07 (+3.27%)
     
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • DOW

    30,046.24
    +454.97 (+1.54%)
     
  • CRUDE OIL

    45.20
    +0.29 (+0.65%)
     
  • GOLD FUTURES

    1,810.20
    +5.60 (+0.31%)
     
  • NIKKEI 225

    26,296.86
    +131.27 (+0.50%)
     
  • HANG SENG

    26,669.75
    +81.55 (+0.31%)
     
  • DAX

    13,255.89
    -36.55 (-0.27%)
     
  • CAC 40

    5,553.93
    -4.49 (-0.08%)
     

Global Molecular Diagnostics Industry

ReportLinker
·24-min read

With PCR Tests Considered as the Gold Standard of Covid-19 Testing, Molecular Diagnostics Sees a 20. 7% Spike in Revenues. The global market for Molecular Diagnostics is expected witness revenues spike by 20.

New York, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Molecular Diagnostics Industry" - https://www.reportlinker.com/p090566/?utm_source=GNW
7% in the year 2020 and thereafter continue to grow and reach US$19.9 billion by the year 2027, trailing a post COVID-19 CAGR of 9.8% over the analysisperiod2020 through 2027. Molecular diagnostic testing for COVID-19 is rapidly evolving each week as global infections continue to surge. Countries worldwide are stepping up testing rates significantly in a bid to control the spread of infections & mortality rates. India which is now in the eye of the pandemic storm is currently carrying out 1 million COVID-19 tests daily. The pressing requirement for massive and universal testing is leading to introduction of various technologies for COVID-19 diagnostics, providing access to new tests in response to the pandemic. These diagnostic techniques, along with approaches to develop new vaccines or therapies, rely heavily on molecules from the coronavirus, including nucleic acids such as DNA or RNA and proteins. COVID-19 diagnostics essentially screen samples for the viral RNA or the presence of antibodies for viral RNA. While viral RNA tests identify presence of SARS-CoV-2 infection from swab samples by reverse transcription of polymerase chain reaction (RT-PCR), immunoassay-based antibody tests delve deeper into the serum and diagnose presence of antibodies produced in the body and quantify the impact and resultant immunity attained. While RT-PCR tests are direct tests, antibody tests are to be paired with viral RNA tests and are not conclusive on their own and sometimes yield inconsistent results if the individual’s immune system produces antibodies later than the time of the test.

As the gold standard in molecular diagnostics, PCR isa dominant way through which global healthcare systems are testing for Covid-19. These tests work by detecting the viral genomic material of the virus namely ribonucleic acid (RNA) which remains in the body while the virus replicates. Testing for COVID-19 detects genetic material of the virus from the lower and upper respiratory tract. Molecular tests use swab collection of the specimen from the mouth or nose of a person. The specimen is processed for the specific ribonucleic acid (RNA) or genetic signature of the SARS-CoV-2. Molecular tests are commonly used in acute respiratory infections for detecting the viral genetic material in specimens. The approach relies on reverse transcription polymerase chain reaction (RT-PCR) that involves copying and comparison of the genetic material from a specimen to the virus’ genetic sequence. Molecular testing uses swab or saliva samples to detect the virus. The swab test involves insertion of a six inch swab into the back side of the nasal passage. The swab is rotated several times for collecting the sample from both nostrils, which is sent to a laboratory for testing. Abbott Laboratories has launched a point-of-care swab test intended to deliver test results in around five minutes. The availability of point-of-care or portable test kits allows sample collection in provider offices and even at a drive-thru site.

The FDA has recently authorized the foremost molecular test that considers saliva specimen. Offered by Rutgers’ RUCDR Infinite Biologics, the test is accurate and addresses shortage of swabs. The FDA has allowed several companies to distribute molecular tests and notified various players to start testing people using internally-validated tests. Molecular diagnostics are gaining growing confidence in COVID 19 testing by virtue of their high specificity and accuracy RT-PCR tests in comparison with the cost efficient alternative
antibody tests that falter at authenticity of findings due to inconclusive early stage viral presence. The phenomenal rise in the COVID cases worldwide is poised to grow the market for molecular diagnostics multi-fold. With the recovery across the Asian, European and American markets falling into different stages, it is vital for the molecular diagnostics companies to be present in the right markets at the right time, vet their resources, scale up production, and optimize supply chains to overcome market specific hurdles, shortages, supply disruptions to pocket healthy volumes as long as the demand exists. Volumes may recede as the global infections go down gradually, or are contingent upon the development of the vaccine by 2021. In the post COVID-19 period, demand for molecular diagnostics will grow stronger with pent-up demand for infectious disease testing such as tuberculosis, hepatitis C, hepatitis B, HPV, and also STDs.

Competitors identified in this market include, among others,

  • Abbott Laboratories

  • Becton, Dickinson and Company

  • bioMérieux SA

  • Cepheid

  • F. Hoffmann-La Roche Ltd.

  • Grifols International S.A.

  • Hologic Inc.

  • QIAGEN N.V.

  • Quest Diagnostics Inc.

  • Siemens Healthineers

  • Tecan Group Ltd.

  • Thermo Fischer Scientific Inc.




Read the full report: https://www.reportlinker.com/p090566/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
Molecular Diagnostics Receive Healthy Booster from CoVid-19 Tests II-2
Exhibit 1: Total Number of COVID-19 Tests Conducted in the Most
Impacted Countries II-3
Molecular Diagnostics Receive Healthy Booster from CoVid-19 Tests II-4
RT-PCR Emerges as the Frontline Technology for Testing COVID-19 II-5
Performance Analysis of COVID-19 Tests II-6
Need of the Hour: RT-PCR Shortages to be Tackled Effectively by
Molecular Diagnostics Companies II-6
Molecular Diagnostic Companies Re-strategize Logistics to Stay
at the Top End of the Game II-6
Select Tests Introduced for COVID-19 II-7
COVID-19 Plunges Fortunes of Non- COVID Diagnostics II-8
Cancer Testing Dives During First Half of 2020 II-8
Myeloproliferative Neoplasm Tests Suffer the Brunt of CoVID-19
Curbs II-8
Labs Embark New Journeys to Retain Overall Volumes II-9
Molecular Diagnostics: An Introduction II-9
Types of Molecular Diagnostics Tests II-11
Market Outlook II-12
Major Growth Drivers II-14
Developing Countries Offer Strong Growth Prospects II-15
PCR Technology Leads the MDx Market II-15
Infectious Diseases: The Largest Application Market II-16
Reagents and Kits Dominate the Molecular Diagnostics Market II-17
Competition II-17
Exhibit 2: Global Molecular Diagnostics Market by Leading
Player (2019) II-18
Exhibit 3: Global Molecular Diagnostics Market for Clostridium
difficile by Leading Player: 2019 II-19
Pharmaceutical Firms Carve their Niche in Molecular Diagnostic
Market II-19
Recent Market Activity II-20

2. FOCUS ON SELECT PLAYERS II-24

3. MARKET TRENDS & DRIVERS II-26
Faster Screening Necessitates Point-of-Care Diagnostics for
COVID-19 II-26
Molecular Diagnostics Market Eyes Transformational Impact of
Proactive Diagnostics II-26
Next-Generation Sequencing to Emerge as Novel Technique in
Fight with COVID-19 II-27
Isothermal Amplification: An Alternative to RT-PCR for COVID-19
Testing II-28
Technological Innovations Set to Drive Market Growth II-29
New Product Developments II-31
Digitalization, Automation and AI Trends Reshape Growth II-32
Growing Role of Molecular Diagnostics in Personalized Medicine II-32
Exhibit 4: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019, 2021, 2023 and 2025 II-34
Companion Diagnostics Drive Personalized Medicine II-34
Biomarkers as Companion Diagnostics II-35
Oncology-Based Molecular Diagnostics Lead Growth II-35
Exhibit 5: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-37
Exhibit 6: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018 II-38
Exhibit 7: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018 II-39
New Applications Hold Promising Potential II-39
Next-Generation Sequencing (NGS) Technologies Keep Up the Momentum II-40
Rising Emphasis on Lab Automation to Augur Well for Market Growth II-41
Exhibit 8: World Laboratory Automation Market in US$ Billion
for Years 2018, 2020, 2022, 2024 & 2026 II-42
Nanotechnology for Molecular Diagnostics II-42
Growing Popularity of Chemo-Sensitivity Testing of CTCs II-43
Genetic Disease Testing Offers Bright Prospects II-43
Genetic Testing to Aid in Personalized Medicine II-44
Pharmacogenomics Development Augurs Growth of Genetic Testing
Market II-45
Non-Invasive Prenatal Diagnostics - The Way Ahead II-46
Nucleic Acid Amplification Methods for Detection of
Antimicrobial Resistance II-46
Growing Incidence of Infectious Diseases Spurs Opportunities II-47
Exhibit 9: Infectious Diseases Remain Major Cause of Death in
Under Developed Regions: Breakdown of Leading Causes of Death
in Sub-Saharan Africa (in %) II-49
PCR Plays a Vital Role in the Diagnosis of Infectious Diseases II-49
Rising Incidence of Hospital Acquired Infections Propels Market
Growth II-50
Greater Number of Tests for HIV and Sexually Transmitted
Diseases Amplify Growth II-51
Exhibit 10: Global HIV Prevalence: Number of People Living with
AIDs (in Thousands) by Region for 2018 II-52
Exhibit 11: Number of AIDS-Related Deaths (in Thousands) by
Region for 2018 II-53
Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer
Disease II-53
Home HIV Testing Emerges as a Lucrative Option II-54
Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market II-54
Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing II-55
Exhibit 12: Hepatitis B prevalence Worldwide by Region II-56
HPV Testing: A Fast Growing Segment in the Molecular Diagnostic
Testing Market II-57
Exhibit 13: HPV Associated Disorders Market by Indication: 2019 II-58
Cervical Cancer: Rising Incidence & Mortality Enhances Need for
Testing II-58
Exhibit 14: Number of New Cervix Uteri Cases in the World by
Region (2018) II-60
Molecular based Tests Ingrain Roots in Blood Donor Screening
Segment II-60
Rise in Healthcare Expenditure to Drive Growth II-61
Exhibit 15: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-63
Aging Population Drives Molecular Diagnostics Market II-63
Exhibit 16: Elderly Healthcare Expenditure as a % of GDP II-64
Exhibit 17: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050 II-65

4. GLOBAL MARKET PERSPECTIVE II-66
Table 1: World Current & Future Analysis for Molecular
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-66

Table 2: World Historic Review for Molecular Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-67

Table 3: World 15-Year Perspective for Molecular Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027 II-68

Table 4: World Current & Future Analysis for Reagents & Kits by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-69

Table 5: World Historic Review for Reagents & Kits by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-70

Table 6: World 15-Year Perspective for Reagents & Kits by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-71

Table 7: World Current & Future Analysis for Instruments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-72

Table 8: World Historic Review for Instruments by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 II-73

Table 9: World 15-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-74

Table 10: World Current & Future Analysis for Software &
Service by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-75

Table 11: World Historic Review for Software & Service by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-76

Table 12: World 15-Year Perspective for Software & Service by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-77

Table 13: World Current & Future Analysis for PCR by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 II-78

Table 14: World Historic Review for PCR by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 II-79

Table 15: World 15-Year Perspective for PCR by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027 II-80

Table 16: World Current & Future Analysis for In-Situ
Hybridization by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-81

Table 17: World Historic Review for In-Situ Hybridization by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-82

Table 18: World 15-Year Perspective for In-Situ Hybridization
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-83

Table 19: World Current & Future Analysis for Isothermal
Amplification by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-84

Table 20: World Historic Review for Isothermal Amplification by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-85

Table 21: World 15-Year Perspective for Isothermal
Amplification by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027 II-86

Table 22: World Current & Future Analysis for Sequencing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-87

Table 23: World Historic Review for Sequencing by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 II-88

Table 24: World 15-Year Perspective for Sequencing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-89

Table 25: World Current & Future Analysis for Chips &
Microarrays by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-90

Table 26: World Historic Review for Chips & Microarrays by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-91

Table 27: World 15-Year Perspective for Chips & Microarrays by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-92

Table 28: World Current & Future Analysis for Other
Technologies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-93

Table 29: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-94

Table 30: World 15-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-95

Table 31: World Current & Future Analysis for Infectious
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-96

Table 32: World Historic Review for Infectious Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-97

Table 33: World 15-Year Perspective for Infectious Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-98

Table 34: World Current & Future Analysis for Oncology Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-99

Table 35: World Historic Review for Oncology Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-100

Table 36: World 15-Year Perspective for Oncology Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-101

Table 37: World Current & Future Analysis for Genetic Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-102

Table 38: World Historic Review for Genetic Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-103

Table 39: World 15-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-104

Table 40: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-105

Table 41: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 II-106

Table 42: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027 II-107

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
Market Overview III-1
Exhibit 18: Healthcare Spending as a % of GDP in the US: 2010-2020 III-2
US Emerges as a Major Market for COVID-19 Tests III-3
FDA Plays Instrumental Role in Influx of New Tests III-3
Select COVID-19 Test Kits with FDA Authorization III-4
Exhibit 19: Cumulative Number of COVI-19 Tests Performed in the
US (In ?000): 31-Mar-30 July 2020 III-5
NIH Launches Initiative to Encourage Innovation III-6
Infectious Disease Testing Contributes to High Growth III-6
Ageing Demographics: Major Driving Factor III-6
Exhibit 20: US Elderly Population: Expected Growth Rates Over
the Years 2005-2025 III-7
Increasing Incidence of Chronic Diseases Drives Focus onto
Molecular Diagnostics III-7
Rising Incidence of Cancer: A Major Growth Driver III-8
Exhibit 21: Leading Sites of New Cancer Cases in Males: 2020 III-8
Exhibit 22: Leading Sites of New Cancer Cases in Females: 2020 III-9
Molecular Diagnostics Tests Gain Share in STD Testing Domain III-9
HPV Testing Market: A Review III-10
Exhibit 23: Prevalence of HPV in the US by Age III-11
US Personalized Medicine Market to Offer Significant Opportunities III-11
Companion Diagnostics Market in the US III-12
Burgeoning Potential for Genetic Testing III-12
Paradigm Shift amongst Consumers Spurs DTC Genetic Testing Market III-13
Market Analytics III-14
Table 43: USA Current & Future Analysis for Molecular
Diagnostics by Component - Reagents & Kits, Instruments and
Software & Service - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-14

Table 44: USA Historic Review for Molecular Diagnostics by
Component - Reagents & Kits, Instruments and Software & Service
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 III-15

Table 45: USA 15-Year Perspective for Molecular Diagnostics by
Component - Percentage Breakdown of Value Sales for Reagents &
Kits, Instruments and Software & Service for the Years 2012,
2020 & 2027 III-16

Table 46: USA Current & Future Analysis for Molecular
Diagnostics by Technology - PCR, In-Situ Hybridization,
Isothermal Amplification, Sequencing, Chips & Microarrays and
Other Technologies - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-17

Table 47: USA Historic Review for Molecular Diagnostics by
Technology - PCR, In-Situ Hybridization, Isothermal
Amplification, Sequencing, Chips & Microarrays and Other
Technologies Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 III-18

Table 48: USA 15-Year Perspective for Molecular Diagnostics by
Technology - Percentage Breakdown of Value Sales for PCR,
In-Situ Hybridization, Isothermal Amplification, Sequencing,
Chips & Microarrays and Other Technologies for the Years 2012,
2020 & 2027 III-19

Table 49: USA Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease, Oncology
Testing, Genetic Testing and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-20

Table 50: USA Historic Review for Molecular Diagnostics by
Application - Infectious Disease, Oncology Testing, Genetic
Testing and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 III-21

Table 51: USA 15-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdown of Value Sales for
Infectious Disease, Oncology Testing, Genetic Testing and Other
Applications for the Years 2012, 2020 & 2027 III-22

CANADA III-23
Table 52: Canada Current & Future Analysis for Molecular
Diagnostics by Component - Reagents & Kits, Instruments and
Software & Service - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-23

Table 53: Canada Historic Review for Molecular Diagnostics by
Component - Reagents & Kits, Instruments and Software & Service
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 III-24

Table 54: Canada 15-Year Perspective for Molecular Diagnostics
by Component - Percentage Breakdown of Value Sales for Reagents &
Kits, Instruments and Software & Service for the Years 2012,
2020 & 2027 III-25

Table 55: Canada Current & Future Analysis for Molecular
Diagnostics by Technology - PCR, In-Situ Hybridization,
Isothermal Amplification, Sequencing, Chips & Microarrays and
Other Technologies - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-26

Table 56: Canada Historic Review for Molecular Diagnostics by
Technology - PCR, In-Situ Hybridization, Isothermal
Amplification, Sequencing, Chips & Microarrays and Other
Technologies Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 III-27

Table 57: Canada 15-Year Perspective for Molecular Diagnostics
by Technology - Percentage Breakdown of Value Sales for PCR,
In-Situ Hybridization, Isothermal Amplification, Sequencing,
Chips & Microarrays and Other Technologies for the Years 2012,
2020 & 2027 III-28

Table 58: Canada Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease, Oncology
Testing, Genetic Testing and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-29

Table 59: Canada Historic Review for Molecular Diagnostics by
Application - Infectious Disease, Oncology Testing, Genetic
Testing and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 III-30

Table 60: Canada 15-Year Perspective for Molecular Diagnostics
by Application - Percentage Breakdown of Value Sales for
Infectious Disease, Oncology Testing, Genetic Testing and Other
Applications for the Years 2012, 2020 & 2027 III-31

JAPAN III-32
Market Overview III-32
Brief Note on COVID-19 Testing in Japan III-32
Demographics Drive Market Growth III-32
Exhibit 24: Breakdown of Population by Age Group in Japan:
2010, 2020, and 2025 III-32
Market Analytics III-33
Table 61: Japan Current & Future Analysis for Molecular
Diagnostics by Component - Reagents & Kits, Instruments and
Software & Service - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-33

Table 62: Japan Historic Review for Molecular Diagnostics by
Component - Reagents & Kits, Instruments and Software & Service
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 III-34

Table 63: Japan 15-Year Perspective for Molecular Diagnostics
by Component - Percentage Breakdown of Value Sales for Reagents &
Kits, Instruments and Software & Service for the Years 2012,
2020 & 2027 III-35

Table 64: Japan Current & Future Analysis for Molecular
Diagnostics by Technology - PCR, In-Situ Hybridization,
Isothermal Amplification, Sequencing, Chips & Microarrays and
Other Technologies - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-36

Table 65: Japan Historic Review for Molecular Diagnostics by
Technology - PCR, In-Situ Hybridization, Isothermal
Amplification, Sequencing, Chips & Microarrays and Other
Technologies Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 III-37

Table 66: Japan 15-Year Perspective for Molecular Diagnostics
by Technology - Percentage Breakdown of Value Sales for PCR,
In-Situ Hybridization, Isothermal Amplification, Sequencing,
Chips & Microarrays and Other Technologies for the Years 2012,
2020 & 2027 III-38

Table 67: Japan Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease, Oncology
Testing, Genetic Testing and Other Applications - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-39

Table 68: Japan Historic Review for Molecular Diagnostics by
Application - Infectious Disease, Oncology Testing, Genetic
Testing and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 III-40

Table 69: Japan 15-Year Perspective for Molecular Diagnostics
by Application - Percentage Breakdown of Value Sales for
Infectious Disease, Oncology Testing, Genetic Testing and Other
Applications for the Years 2012, 2020 & 2027 III-41

CHINA III-42
Market Overview III-42
COVID-19 Testing: An Overview III-42
HPV Testing in China III-43
Market Analytics III-44
Table 70: China Current & Future Analysis for Molecular
Diagnostics by Component - Reagents & Kits, Instruments and
Software & Service - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 III-44

Table 71: China Historic Review for Molecular Diagnostics by
Component - Reagents & Kits, Instruments and Software & Service
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 III-45

Table 72: China 15-Year Perspective for Molecular Diagnostics
by Component - Percentage Breakdown of Value Sales for Reagents &
Kits, Instruments and Software & Service for the Years 2012,
2020 & 2027 III-46

Table 73: China Current & Future Analysis for Molecular
Diagnostics by Technology - PCR, In-Situ Hybridization,
Isothermal Amplification, Sequencing, Chips & Microarrays and

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p090566/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001